Science and Technology Fund Sample Clauses

Science and Technology Fund. The Adviser has voluntarily agreed to waive 0.05% of its advisory fee otherwise payable on the portion of the aggregate net assets of Science & Technology Fund between and including $250,000,001 and $500,000,000 that are managed by Allianz Global Investors U.S. LLC.
Sample 1Sample 2Sample 3
AutoNDA by SimpleDocs
Science and Technology Fund. The Adviser voluntarily agrees to waive its advisory fee for the Science & Technology Fund so that the amount retained by the Adviser after payment of the subadvisory fee does not exceed 0.45% of the Fund’s average daily net assets. This voluntary management fee waiver may be terminated at any time by the Adviser upon notice to the Trust.
Sample 1
Science and Technology Fund. Net Assets Fee ---------- --- Up to $1 billion 0.85% of net assets Over $1 billion and up to $2 billion 0.83% of net assets Over $2 billion and up to $3 billion 0.80% of net assets Over $3 billion 0.76% of net assets As Amended and Effective June 30, 1999. XXXXXXX & XXXX ADVISORS GLOBAL BOND FUND, INC. A cash fee computed each day on net asset value for the Fund at the annual rates listed below: Net Assets Fee ---------- --- Up to $500 million 0.625% of net assets Over $500 million and up to $1 billion 0.60% of net assets Over $1 billion and up to $1.5 billion 0.55% of net assets Over $1.5 billion 0.50% of net assets As Amended and Effective June 30, 1999. XXXXXXX & XXXX ADVISORS GOVERNMENT SECURITIES FUND, INC. A cash fee computed each day on net asset value for the Fund at the annual rates listed below: Net Assets Fee ---------- --- Up to $500 million 0.50% of net assets Over $500 million and up to $1 billion 0.45% of net assets Over $1 billion and up to $1.5 billion 0.40% of net assets Over $1.5 billion 0.35% of net assets As Amended and Effective June 30, 1999. XXXXXXX & XXXX ADVISORS HIGH INCOME FUND, INC. A cash fee computed each day on net asset value for the Fund at the annual rates listed below: Net Assets Fee ---------- --- Up to $500 million 0.625% of net assets Over $500 million and up to $1 billion 0.60% of net assets Over $1 billion and up to $1.5 billion 0.55% of net assets Over $1.5 billion 0.50% of net assets As Amended and Effective June 30, 1999. XXXXXXX & XXXX ADVISORS INTERNATIONAL GROWTH FUND, INC. A cash fee computed each day on net asset value for the Fund at the annual rates listed below: Net Assets Fee ---------- --- Up to $1 billion 0.85% of net assets Over $1 billion and up to $2 billion 0.83% of net assets Over $2 billion and up to $3 billion 0.80% of net assets Over $3 billion 0.76% of net assets As Amended and Effective June 30, 1999. XXXXXXX & XXXX ADVISORS MUNICIPAL BOND FUND, INC. A cash fee computed each day on net asset value for the Fund at the annual rates listed below: Net Assets Fee ---------- --- Up to $500 million 0.525% of net assets Over $500 million and up to $1 billion 0.50% of net assets Over $1 billion and up to $1.5 billion 0.45% of net assets Over $1.5 billion 0.40% of net assets As Amended and Effective June 30, 1999. XXXXXXX & XXXX ADVISORS MUNICIPAL HIGH INCOME FUND, INC. A cash fee computed each day on net asset value for the Fund at the annual rates listed below: Net Assets Fee ---------- --- Up to $50...
Sample 1
Science and Technology Fund. Net Assets Fee Up to$1 billion 0.85% of net assets Over $1 billion and up to $2 billion 0.83% of net assets Over $2 billion and up to $3 billion 0.80% of net assets Over $3 billion 0.76% of net assets Small Cap Growth Fund Net Assets Fee Up to $1 billion 0.85% of net assets Over $1 billion and up to $2 billion 0.83% of net assets Over $2 billion and up to $3 billion 0.80% of net assets Over $3 billion 0.76% of net assets Tax-Managed Equity Fund Net Assets Fee Up to $1 billion 0.65% of net assets Over $1 billion and up to $2 billion 0.60% of net assets Over $2 billion and up to $3 billion 0.55% of net assets Over $3 billion 0.50% of net assets As originally Amended and Effective June 30, 2000. As Amended and Restated and Effective November 16, 2005. As Amended, Effective and Approved May 15, 2009. *If a Fund’s net assets are less than $25 million, IICO has agreed to voluntarily waive the management fee, subject to its right to change or modify this waiver.
Sample 1
Science and Technology Fund. Net Assets Fee Up to $1 billion 0.85% of net assets Over $1 billion and up to $2 billion 0.83% of net assets Over $2 billion and up to $3 billion 0.80% of net assets Over $3 billion 0.76% of net assets Small Cap Growth Fund Net Assets Fee Up to $1 billion 0.85% of net assets Over $1 billion and up to $2 billion 0.83% of net assets Over $2 billion and up to $3 billion 0.80% of net assets Over $3 billion 0.76% of net assets Approved May 17, 2000: Capital Appreciation Fund Net Assets Fee Up to $1 billion 0.65% of net assets Over $1 billion and up to $2 billion 0.60% of net assets Over $2 billion and up to $3 billion 0.55% of net assets Over $3 billion 0.50% of net assets Large Cap Growth Fund Net Assets Fee Up to $1 billion 0.70% of net assets Over $1 billion and up to $2 billion 0.65% of net assets Over $2 billion and up to $3 billion 0.60% of net assets Over $3 billion 0.55% of net assets Mid Cap Growth Fund Net Assets Fee Up to $1 billion 0.85% of net assets Over $1 billion and up to $2 billion 0.83% of net assets Over $2 billion and up to $3 billion 0.80% of net assets Over $3 billion 0.76% of net assets Money Market Fund A cash fee computed each day on net asset value for the Fund at the annual rate of 0.40% of net assets. Approved 11/16/05: Energy Fund Net Assets Fee Up to $1 billion 0.85% of net assets Over $1 billion and up to $2 billion 0.83% of net assets Over $2 billion and up to $3 billion 0.80% of net assets Over $3 billion 0.76% of net assets Effective 10/1/07: Core Equity Fund Net Assets Fee Up to $1 billion 0.70% of net assets Over $1 billion and up to $2 billion 0.65% of net assets Over $2 billion and up to $3 billion 0.60% of net assets Over $3 billion and up to $5 billion 0.55% of net assets Over $5 billion and up to $6 billion 0.525% of net assets Over $6 billion 0.50% of net assets *If a Fund’s net assets are less than $25 million, IICO has agreed to voluntarily waive the management fee, subject to its right to change or modify this waiver.
Sample 1

Related to Science and Technology Fund

  • Technology License 4.1 Unless any event described in Article 2.2 or 2.3 of this Agreement occurs, all of the technology required to be licensed for any of Party B’s business shall be provided by Party A on an exclusive basis. Party A will try its best to license Party B to use the technology owned by Party A, or re-license Party B to use the technology as approved by the owner.

  • Technology For purposes of this Agreement, “Technology” means all Software, information, designs, formulae, algorithms, procedures, methods, techniques, ideas, know-how, research and development, technical data, programs, subroutines, tools, materials, specifications, processes, inventions (whether or not patentable and whether or not reduced to practice), apparatus, creations, improvements and other similar materials, and all recordings, graphs, drawings, reports, analyses, and other writings, and other embodiments of any of the foregoing, in any form or media whether or not specifically listed herein. Further, for purposes of this Agreement, “Software” means any and all computer programs, whether in source code or object code; databases and compilations, whether machine readable or otherwise; descriptions, flow-charts and other work product used to design, plan, organize and develop any of the foregoing; and all documentation, including user manuals and other training documentation, related to any of the foregoing.

  • Background Technology List here prior contracts to assign Inventions that are now in existence between any other person or entity and you. [ ] List here previous Inventions which you desire to have specifically excluded from the operation of this Agreement. Continue on reverse side if necessary.

  • New Technology If New Technology becomes available from any source, including Supplier, then KP may evaluate and contract with any supplier so that KP will have access to New Technology at all times. If Supplier cannot offer New Technology at comparable or lower prices, KP may either (a) amend contract pricelist to add Supplier's New Technology at a mutually agreed-upon price; or (b) contract with other suppliers for New Technology. Regardless of whether New Technology is added to this Agreement, Supplier and KP will negotiate in good faith to equitably adjust the pricing for any current Product under this Agreement affected by the New Technology.

  • Information Technology The Company’s and the Subsidiaries’ information technology assets and equipment, computers, systems, networks, hardware, software, websites, applications, and databases (collectively, “IT Systems”) operate and perform in all material respects as required in connection with the operation of the business of the Company and the Subsidiaries as currently conducted. The Company, and the Subsidiaries maintain commercially reasonable controls, policies, procedures, and safeguards to maintain and protect their material confidential information and the integrity, continuous operation, redundancy and security of all IT Systems and all personal, personally identifiable, sensitive, confidential or regulated data (“Personal Data”) processed and stored thereon, and to the knowledge of the Company, there have been no breaches, incidents, violations, outages, compromises or unauthorized uses of or accesses to same, except for those that have been remedied without material cost or liability or the duty to notify any other person, nor any incidents under internal review or investigations relating to the same. The Company and the Subsidiaries are presently in compliance in all material respects with all applicable laws or statutes and all applicable judgments, orders, rules and regulations of any court or arbitrator or governmental or regulatory authority, internal policies and contractual obligations relating to the privacy and security of IT Systems and Personal Data and to the protection of such IT Systems and Personal Data from unauthorized use, access, misappropriation or modification, except for any such noncompliance that would not have a Material Adverse Effect.

  • Technology Access Fee In consideration of the licenses and rights granted to Regado herein, Regado shall, as of the date immediately preceding the closing (the “Closing”) of the first equity financing of Regado in which Regado is assigned a pre-money valuation of not less than [***] dollars ($[***]), issue to Archemix fully-paid and non-assessable shares of common stock of Regado equal to [***] percent ([***]%) of the total number of equity shares of Regado, on a fully diluted basis, immediately prior to the issuance of shares at the Closing. Regado shall deliver written notice of the Closing to Archemix at least [***] business days prior to such Closing in accordance with the notice provisions contained in Section 14.1 of this Agreement. Archemix and Regado shall enter into such agreements relating to the issuance of the common stock as are customary under such circumstances. For the purpose of this Agreement, “fully diluted basis” shall mean the aggregate of (a) the number of shares of common stock issued and outstanding on the determination date, (b) the number of shares of common stock issuable upon exercise, exchange or conversion of all exercisable, exchangeable or convertible securities outstanding on the determination date, assuming such securities were exercised, exchanged or converted on the determination date (without regard to whether such securities are actually exercisable, exchangeable or convertible on the determination date) and (c) the number of shares of common stock issuable pursuant to any other obligation or agreement of, or right granted by, Regado, whether vested or unvested, contingent or otherwise.

  • Inventions, Ideas, Processes, and Designs All inventions, ideas, processes, programs, software, and designs (including all improvements) (i) conceived or made by the Executive during the course of his or her employment with the Company (whether or not actually conceived during regular business hours) and for a period of six months subsequent to the termination (whether by expiration of the Term or otherwise) of such employment with the Company, and (ii) related to the business of the Company, shall be disclosed in writing promptly to the Company and shall be the sole and exclusive property of the Company, and the Executive hereby assigns any such inventions to the Company. An invention, idea, process, program, software, or design (including an improvement) shall be deemed related to the business of the Company if (a) it was made with the Company’s funds, personnel, equipment, supplies, facilities, or Confidential Information, (b) results from work performed by the Executive for the Company, or (c) pertains to the current business or demonstrably anticipated research or development work of the Company. The Executive shall cooperate with the Company and its attorneys in the preparation of patent and copyright applications for such developments and, upon request, shall promptly assign all such inventions, ideas, processes, and designs to the Company. The decision to file for patent or copyright protection or to maintain such development as a trade secret, or otherwise, shall be in the sole discretion of the Company, and the Executive shall be bound by such decision. The Executive hereby irrevocably assigns to the Company, for no additional consideration, the Executive’s entire right, title and interest in and to all work product and intellectual property rights, including the right to sxx, counterclaim and recover for all past, present and future infringement, misappropriation or dilution thereof, and all rights corresponding thereto throughout the world. Nothing contained in this Agreement shall be construed to reduce or limit the Company’s rights, title or interest in any work product or intellectual property rights so as to be less in any respect than the Company would have had in the absence of this Agreement. If applicable, the Executive shall provide as a schedule to this Agreement, a complete list of all inventions, ideas, processes, and designs, if any, patented or unpatented, copyrighted or otherwise, or non-copyrighted, including a brief description, which he or she made or conceived prior to his or her employment with the Company and which therefore are excluded from the scope of this Agreement. References to the Company in this Section 12 shall include the Company, its subsidiaries and affiliates.

  • Technology and Intellectual Property (a) Schedule 2.22(a) sets forth a complete and correct list of all (i) registered trademarks, service marks, domain names, copyrights and patents; (ii) applications for registration or grant of any of the foregoing; (iii) unregistered trademarks, service marks, trade names, logos and assumed names; and (iv) licenses for any of the foregoing, in each case, owned by or for the benefit of the Company or a Company Subsidiary, or used in or necessary to conduct the Company’s or a Company Subsidiary’s business as presently conducted. The items on Schedule 2.22(a), together with all other trademarks, service marks, trade names, logos, assumed names, patents, copyrights, trade secrets, computer software, licenses, formulae, customer lists or other databases, business application designs and inventions currently used in or necessary to conduct the businesses of the Company or of a Company Subsidiary, constitute the “Intellectual Property.”

  • Manufacturing Technology Transfer With respect to each Technology Transfer Product, upon AbbVie’s written request after the Inclusion Date for the Included Target to which such Technology Transfer Product is Directed, Morphic shall effect a full transfer to AbbVie or its designee (which designee may be an Affiliate or a Third Party manufacturer) of all Morphic Know-How and Joint Know-How relating to the then-current process for the Manufacture of such Technology Transfer Product (the “Manufacturing Process”) and to implement the Manufacturing Process at facilities designated by AbbVie (such transfer and implementation, as more fully described in this Section 5.3, the “Manufacturing Technology Transfer”). To assist with the Manufacturing Technology Transfer, Morphic will make its personnel reasonably available to AbbVie during normal business hours for up to [***] FTE hours with respect to each Included Target (in each case, free of charge to AbbVie) to transfer and implement the Manufacturing Process under this Section 5.3. Thereafter, if requested by AbbVie, Morphic shall continue to perform such obligations; provided, that AbbVie will reimburse Morphic for its full-time equivalent (FTE) costs (for clarity, in excess of [***] FTE hours) and any reasonable and verifiable out-of-pocket costs incurred in providing such assistance. CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE COMPANY IF PUBLICLY DISCLOSED.

  • Licensed Technology The term "Licensed Technology" shall mean the ------------------- Licensed Patents, plus all improvements thereto developed by Licensor, and all related data, know-how and technology.

Time is Money Join Law Insider Premium to draft better contracts faster.